Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03107091 · ClinicalTrials.gov registry record · Phase 2
Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites
A Phase 2 study, sponsored by BioVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03107091: Completed Phase 2 study, sponsored by BioVie.
NCT03107091 is a Phase 2 study that has completed, run by BioVie. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03107091, a Phase 2 study, has completed, sponsored by BioVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Low-dose continuous infusion of terlipressin will be administered to six cirrhotic patients with refractory ascites.
Primary Outcome
Rate of treatment emergent adverse events assessed by physical examination and laboratory safety
Interventions
- DRUG Terlipressin acetate continuous infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-07-15 |
| Est. Completion | 2019-04-25 |
| Phase | Phase 2 |
What the finished NCT03107091 record still lists
NCT03107091 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Terlipressin acetate continuous infusion is the first listed.
NCT03107091 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03107091 about?
NCT03107091 is a clinical study titled "Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites". Low-dose continuous infusion of terlipressin will be administered to six cirrhotic patients with refractory ascites.
What is the current status of trial NCT03107091?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2017-07-15. Estimated completion is 2019-04-25.
What interventions are being tested in trial NCT03107091?
The interventions under investigation include: Terlipressin acetate continuous infusion (DRUG).
Who is sponsoring clinical trial NCT03107091?
This trial is sponsored by BioVie, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03107091's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI